drugset / Trial / NCT00562237
Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine
RandomizedParallel-groupDouble-blindPrevention
Summary
Several combinations of H5N1 antigen concentrations and aluminium-hydroxide adjuvant concentrations will be tested for their safety and capacity to induce a specific immune response.
Timeline
- Start
- 2007-07
- Primary completion
- 2007-11
- Completion
- 2008-09
Outcome
Outcome not reported
Stopped: “This trial discontinued on 20 JUN 2008 because the interim immunogenicity results do not justify these formulations as pandemic vaccine candidates”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S205 | Unknown | 10 ug | Intramuscular |
| Subject | S205 | Unknown | 30 ug | Intramuscular |
| Subject | aluminium hydroxide | Other / unclassified | 500 ug | Intramuscular |
| Subject | aluminium hydroxide | Other / unclassified | 1250 ug | Intramuscular |
Indications
No indication recorded.